SpyGlass Pharma, Inc. Common Stock (SGP) Stock Ticker
Market factors today
Unlock the full SGP picture
About SpyGlass Pharma, Inc. Common Stock
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
SGP stock facts
| Ticker symbol | SGP |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $905.0M |
| CEO | Patrick H. Mooney |
| Employees | 76 |
| Headquarters | Irvine, CA, US |
| IPO date | 2026-02-06 |
| Website | www.spyglasspharma.com |
What you can see for SGP on Tickr
Live SGP price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SGP report.
Rankings
FAQ
What is the ticker symbol for SpyGlass Pharma, Inc. Common Stock?
The ticker symbol for SpyGlass Pharma, Inc. Common Stock is SGP, listed on the NASDAQ Global Market.
What is SGP?
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure…